Symbol | Exchange | Currency |
|---|
Arcutis Biotherapeutics(ARQT) announces thatSue-Jean Linhas been appointed to the company's board of directors, effective June 9, 2021.The company also announces that...
Los Angeles, June 03, 2021 (GLOBE NEWSWIRE) -- Vitiligo Pipeline - Current Treatments, Drug Pipeline and Clinical Trial Outlook | Insights by DelveInsightProminent companies...
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more...
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,430.20 | 2,441.72 | 2,418.96 | -4.93 | -0.20% | 1.10M | NASDAQ | |||
| 331.26 | 332.83 | 328.93 | -1.20 | -0.36% | 13.59M | NASDAQ | |||
| 33.10 | 33.41 | 32.80 | +0.23 | +0.70% | 788.24K | NYSE | |||
| 193.02 | 200.05 | 192.88 | -23.75 | -10.96% | 13.73M | NASDAQ | |||
| 67.34 | 67.94 | 66.78 | -0.05 | -0.07% | 9.54M | NYSE | |||
| 29.32 | 29.35 | 29.13 | +0.14 | +0.48% | 31.09M | NYSE | |||
| 71.44 | 71.49 | 70.33 | +0.97 | +1.38% | 2.89M | NYSE | |||
| 0.931 | 1.01 | 0.00 | -0.079 | -7.78% | 3.56M | NASDAQ | |||
| 211.64 | 213.46 | 211.00 | -1.43 | -0.67% | 12.28M | NYSE | |||
| 220.70 | 227.92 | 220.03 | -5.03 | -2.23% | 8.73M | NYSE | |||
| 1.14 | 1.15 | 1.12 | -0.010 | -0.87% | 145.17K | NASDAQ | |||
| 49.40 | 49.60 | 42.01 | +6.59 | +15.39% | 218.01M | NYSE | |||
| 271.45 | 271.90 | 268.40 | +1.98 | +0.73% | 4.49M | NASDAQ | |||
| 15.85 | 16.19 | 15.68 | +0.220 | +1.41% | 2.00M | NASDAQ | |||
| 61.49 | 62.01 | 61.16 | +0.15 | +0.24% | 10.21M | NYSE |
Arcutis Biotherapeutics Inc is a United States-based biopharmaceutical company. The Company focuses on developing treatments for unmet needs in immune-mediated dermatological diseases or immune-dermatology. Its strategy is to identify and develop treatments against validated biological targets in dermatology that deliver a differentiated clinical profile that addresses shortcomings of existing therapies in targeted indications.